BRAF抗体;BRAF Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using BRAF mouse mAb against Hela (1), HT-29 (2), MOLT4 (3) T47D (4) HePG2 (5) HL-60 (6) and PC-12 (7) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of BEL-7402 cells using BRAF mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using BRAF mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cerebellar tissues using BRAF mouse mAb with DAB staining.    

  
  

BRAF antibodies are tools used in research and diagnostics to detect the BRAF protein, a serine/threonine kinase encoded by the *BRAF* gene. This gene plays a critical role in the MAPK/ERK signaling pathway, regulating cell growth, differentiation, and survival. Mutations in *BRAF*, particularly the V600E substitution, are oncogenic drivers in cancers like melanoma, colorectal cancer, and papillary thyroid carcinoma. BRAF antibodies enable the identification of mutant BRAF proteins, aiding in tumor profiling and guiding targeted therapies.

Therapeutic BRAF inhibitors (e.g., vemurafenib, dabrafenib) were developed to block hyperactive mutant BRAF, suppressing MAPK pathway signaling. However, resistance often arises due to pathway reactivation. In diagnostics, BRAF-specific antibodies help assess mutation status via immunohistochemistry, complementing genetic testing. Research-grade antibodies also facilitate mechanistic studies of BRAF's role in tumorigenesis and drug resistance.

Despite their utility, BRAF antibodies require rigorous validation to ensure specificity, as cross-reactivity with similar kinases (e.g., CRAF) can yield false results. Ongoing advancements aim to improve antibody precision and develop next-generation inhibitors to overcome therapeutic resistance. Overall, BRAF antibodies remain pivotal in both understanding BRAF-driven cancers and advancing personalized oncology approaches.